Local application of otoprotective compounds other than sodium thiosulfate to prevent cisplatin-induced hearing loss: a systematic review.

Drug DelivMay 1, 2026 (epub)
Clinical ResearchPediatricsOncology (Medical)Open access

Amirhossein Masroor, Nienke Streefkerk, Martine Van Grotel et al.

✦ AI-curated · Sources linked

In 30 seconds

This systematic review evaluated the efficacy and safety of locally applied otoprotective agents other than sodium thiosulfate (STS) to prevent cisplatin-induced hearing loss in pediatric cancer patients. The review included 70 preclinical and eight clinical studies, identifying dexamethasone and N-acetylcysteine as the most investigated agents. Dexamethasone showed statistically significant but not clinically relevant benefits in two of three randomized clinical trials.

Key findings

  • Dexamethasone showed statistically significant benefits in two out of three randomized clinical trials.
  • N-acetylcysteine was minimally effective in one randomized clinical trial and one clinical study.
  • The review included 70 preclinical studies and eight clinical studies on otoprotective agents.

Why it matters

Cisplatin-induced hearing loss significantly affects the quality of life in pediatric cancer patients. Understanding alternative otoprotective strategies is crucial for improving patient outcomes and managing treatment-related side effects.

Source

PubMed · PMID 42068011Free full text on PubMed Central

Published in Drug Deliv. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Pediatrics

Clinical ResearchOncology (Medical)

Zamtocabtagene autoleucel, a tandem CD20-CD19-directed CAR T-cell therapy, for second line treatment of large B-cell lymphoma in patients ineligible for transplantation (DALY 2-EU): primary analysis of an open-label, multicentre, randomised phase 2 study.

DALY 2-EU was an open-label, multicentre, randomised phase 2 trial comparing tandem CD20-CD19-directed zamtocabtagene autoleucel (zamto-cel) with R-GemOx in adults with second-line relapsed or refractory large B-cell…

Lancet OncolOct 27, 2026Read summary
Clinical ResearchOncology (Medical)

Neoadjuvant short-course radiotherapy followed by camrelizumab and chemotherapy versus standard of care for locally advanced rectal cancer (UNION): a prespecified interim analysis of a multicentre, open-label, randomised, phase 3 trial.

UNION was a multicentre, open-label, randomised phase 3 trial at nine hospitals in China comparing neoadjuvant short-course radiotherapy followed by camrelizumab plus CAPOX with long-course chemoradiotherapy followed by…

Lancet OncolOct 25, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.